Cannabis Concentrates slide image

Cannabis Concentrates

Large Scale Canadian Cannabis Oil Producer Phase 1: 10,000 sq ft built and operational; 100,000 kg annual capacity Phase 2: funded plans to be complete by end of Q2 2019; additional 150,000kg capacity Building: wholly-owned, closed September 28, 2018 100,000kg of Annual Dry Cannabis Processing Licensed and equipped this phase has 2 production lines and over built support infrastructure. Operational Additional 35,000sq/f Processing Area Located in existing building, available for licensing. कल Additional 150,000kg of Annual Dry Cannabis Processing Licensed space. Custom extractor ordered (largest in Canada) utilizing Phase 1 infrastructure. Ancillary Expansion Unlicensed space to be licensed for new cannabis products, as approved. Non-Cannabis Support Unlicensed space. To be used for non- cannabis operations, storage and shipping (2 existing docks). Operating Expertise Successfully established a team with industry leading expertise in the production of pharmaceutical-grade cannabis concentrates. Under the leadership of Chief Operating Officer, David Mayers, and with the guidance / discipline of our Director of Quality Control & Assurance, Dr. Chris Talpas, MediPharm has developed proprietary methodologies and operational efficiencies which have been leveraged to build a growing library of purified concentrates and distillates. Dr. Dubinsky is our lead scientist of secondary processing. The Company's dynamic production has been achieved through the operation of two production shifts daily, run by approximately 20 production technicians. Operations are led by sector specialists with deep expertise in cannabis extraction, complemented by years of pharmaceutical production experience to GMP standards. Adjunct cannabis consultants provide additional knowledge from their home markets of California (legal adult-use since Jan 2018 with 150 allowable products) and from the United Kingdom with 20+ years chromatophary expertise.
View entire presentation